New York and San Diego, November 5, 2024 – Coastar Therapeutics Inc., a biotechnology company developing novel delivery technologies to supercharge cell and gene therapies, announced that it has been nominated for Best Startup of the 2024 Prix Galien USA Award. 

The Prix Galien USA Award is one of the most prestigious honors in the life sciences industry, recognizing excellence in pharmaceutical, biotechnology, and medical technology innovation. Often referred to as the “Nobel Prize for biopharmaceutical research”, the award celebrates groundbreaking scientific advancements that improve human health. Presented annually, the Prix Galien USA acknowledges the most innovative therapies, devices, and technologies that push the boundaries of medicine and patient care.

“We are deeply honored to be nominated for the Prix Galien USA Award, a recognition that underscores our commitment to transforming the future of genetic medicine,” said Eddie Y. Chung, CEO of Coastar Therapeutics, “At Coastar, we believe that cutting-edge science should translate into real-world impact, and this nomination fuels our mission to develop and deliver life-changing therapies for patients in need around the world“

“This nomination is a testament to the hard work and ingenuity of our scientific team,”said Han L. Lim, Ph.D., Coastar’s Chief Science Officer, “We are pushing the boundaries of gene delivery, and it’s incredibly rewarding to see our technology recognized by such a prestigious institution.“

“This recognition validates the impact of our work and our unwavering dedication to developing transformative therapies,” said Chongyang Luo, Ph.D., Coastar’s COO, “We are excited to continue advancing our platform and bringing new hope to patients worldwide.“

Coastar will be participating the Prix Galien USA award ceremony and gala in New York City.

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnS^TM and eLNPTM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully targeted to tumor or other disease sites. The company is working with a number of global partners to develop next generation therapies.